While this impacts the drug's profitability, only about 25% of Enbrel's revenues come from Part D, mitigating the overall effect on Amgen's financials. Uplizna and Rocatinlimab are two products ...

Data from a Phase 3 study for rocatinlimab is expected this year, while Xaluritamig is a far more speculative opportunity, having not yet progressed into Phase 2 studies. Amgen's CEO, Chairman and ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

Looking ahead, we remain confident that Amgen is well positioned to deliver ... from the first of eight Phase III studies evaluating rocatinlimab in atopic dermatitis. Let's begin with general ...

Data presentation at a medical congress is anticipated in mid-2025. Rocatinlimab is a first-in-class T-cell rebalancing monoclonal antibody targeting the OX40 receptor. The eight study ROCKET ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent ...

So, first, yes, we did see the update on rocatinlimab, and I think that does put some additional ... What we did see with the ...

Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in ...

So, first, yes, we did see the update on rocatinlimab, and I think that does ... What we did see with the Amgen data was significantly less response or efficacy as compared to what was seen ...

Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in ...